Rising rates of depression amid the coronavirus pandemic underscore the need for innovations in mental health care, like psychedelics, according to George Goldsmith, CEO, chairman, and co‑founder of mental health company COMPASS Pathways.

"About 322 million people suffer from depression around the world — and that was before this current pandemic — but about 100 million of those just aren't helped by current treatment," Goldsmith told Cheddar. "So we really focused a lot on, 'how do we bring innovation to patients?'"

COMPASS Pathways is a United Kingdom-based biotech startup, researching a synthetic form of the psychedelic compound, psilocybin, for treatment resistant depression. Its drug, called COMP360, received "breakthrough therapy designation" from the U.S. Food and Drug Administration in 2018, meaning there was evidence it could substantially improve treatment over existing therapies and could move more quickly through drug development. 

"We're working closely with regulators in every country that we're working with to develop clinical trials, and if those clinical trials are successful, then those medicines will be made available to patients," Goldsmith said.

The time is right for innovations in mental health care. Stressors related to the coronavirus pandemic may have tripled rates of depression across the U.S., according to a survey published in JAMA Network Open in early September. Some 27.8 percent of adults reported experiencing depression symptoms amid the pandemic, compared with 8.5 percent previously, according to the survey results. And the burden fell disproportionately on people who had limited financial or social resources. 

"A single experience, a single dose of psilocybin for many people, can create an immediate and sustained benefit for people suffering with depression. And that really intrigued us," Goldsmith said.

COMPASS Pathways debuted on Nasdaq in September in a $146.6 million upsized initial public offering. It's move kicked off a flurry of interest from other psychedelic health and wellness companies looking to go public or uplist for similar access to liquidity and investors. Goldsmith said that for COMPASS Pathways, the move was motivated by expenses associated with the research the company is doing in nine countries. 

"We're committed to really addressing mental health care at scale, and capital, shareholder capital, really helps with that," Goldsmith said.

Share:
More In Business
A US tariff exemption for small orders ends Friday. It’s a big deal.
Low-value imports are losing their duty-free status in the U.S. this week as part of President Donald Trump's agenda for making the nation less dependent on foreign goods. A widely used customs exemption for international shipments worth $800 or less is set to end starting on Friday. Trump already ended the “de minimis” rule for inexpensive items sent from China and Hong Kong, but having to pay import taxes on small parcels from everywhere else likely will be a big change for some small businesses and online shoppers. Purchases that previously entered the U.S. without needing to clear customs will be subject to the origin country’s tariff rate, which can range from 10% to 50%.
Southwest Airlines’ new policy will affect plus-size travelers. Here’s how
Southwest Airlines will soon require plus-size travelers to pay for an extra seat in advance if they can't fit within the armrests of one seat. This change is part of several updates the airline is making. The new rule starts on Jan. 27, the same day Southwest begins assigning seats. Currently, plus-size passengers can pay for an extra seat in advance and later get a refund, or request a free extra seat at the airport. Under the new policy, refunds are still possible but not guaranteed. Southwest said in a statement it is updating policies to prepare for assigned seating next year.
Load More